DOTANOC PET-CT:
New PET-CT radiopharmaceuticals such as 68Ga-DOTA peptides, which directly bind to somatostatin receptors (SSTR) and are usually expressed on NET cell surfaces. 68Ga-DOTA peptide somatostatin receptor imaging is highly sensitive and specific for Neuro-endocrine tumours.
68Ga-DOTA peptide somatostatin receptor imaging is done after injecting 68Ga labeled to peptides like NOC/TOC/TATE by chelating agent DOTA and is useful for staging, restaging after therapy, identification of the site of the unknown primary tumour in patients with proven NET secondary lesions and selecting the patients for cold or hot (peptide receptor radionuclide therapy-PRRT) somatostatin analogues.
68Ga-DOTA peptide SSTR imaging is useful in gastro-entero-pancreatic (GEP) tract tumours like carcinoids, insulinoma, gastrinoma, glucaganoma, VIPoma etc, Non GEP NETs like brochial carcinods,
ectopic ACTH secreting tumours, pheochromocytoma, paragangliomas, recurrent medullary carcinoma thyroid, differentiated thyroid carcinoma with negative iodine scan, merkle cell carcinoma, mesenchymal tumours like osteogenic osteomalacia and others like thymic malignancy and meningioma.
